SOLIGENIX, INC. Finance Lease, Right-of-Use Asset, Amortization
SOLIGENIX, INC. (SNGX) reported Finance Lease, Right-of-Use Asset, Amortization of $5.58 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2022-03-29
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $0.00.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for the quarter ending 2021-09-30 was $1.86K.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $1.86K.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $1.86K.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for fiscal 2021 was $5.58K, a 25.00% decline from fiscal 2020.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for fiscal 2020 was $7.44K, a 0.00% change from fiscal 2019.
- SOLIGENIX, INC. finance lease, right-of-use asset, amortization for fiscal 2019 was $7.44K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.86K derived: sum of 2 quarters · filed 2022-03-29 | $5.58K 10-K · filed 2022-03-29 | |
| 2021-09-30 | $1.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $5.58K 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $3.72K 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $7.44K 10-K · filed 2022-03-29 | |||
| 2019-12-31 | $1.86K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $3.72K derived: sum of 2 quarters · filed 2020-03-30 | $5.58K derived: sum of 3 quarters · filed 2020-03-30 | $7.44K 10-K · filed 2020-03-30 |
| 2019-09-30 | $1.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.72K derived: sum of 2 quarters · filed 2019-11-12 | $5.58K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $3.72K 10-Q · filed 2019-08-13 | ||
| 2019-03-31 | $1.86K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |